Search results for: 'engineering research and development'

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

The global small‑molecule CDMO industry is undergoing a structural transformation driven by increasing molecular complexity, patent expiries, cost pressures, and the strategic need to secure resilient pharmaceutical supply chains. Demand is shifting beyond high‑volume commodity generics toward specialized development and manufacturing capabilities ...

As clinical pipelines globally witness a surge in novel complex therapies, the clinical trial industry demands new tools in predictive analytics to improve trial design, planning, and execution. Artificial intelligence is gaining large-scale recognition as support for decentralized trial designs, thus enabling patient-centric clinical trial designs...

This study explores the transformative potential of organoid technologies in advancing cancer research, precision medicine, and drug discovery. Organoids—3D cell culture systems derived from patient tumors—preserve tumor heterogeneity and provide physiologically relevant models for studying cancer biology, therapeutic response, and resistance mecha...

14 Feb 2025  |  Global  |  Market Research

Proteomics Research Tools and Diagnostics Market, Global, 2024-2030

The Proteomics Industry is Experiencing Transformational Growth Due to Advancements in Proteomics Profiling and Biomarker Discovery

Infographics

×

In the study, Frost & Sullivan examines the global proteomics research tools and diagnostics market, covering different product types, end users, and technologies. The market is projected to register high growth between 2024 and 2030, reaching significant revenue milestones, largely driven by the research and pharmaceutical segments. The increasing...

More than 6,000 molecules are currently in clinical development across the pharmaceutical research and development (R&D) landscape, with more than 11,000 in the preclinical phase. The industry is witnessing the growth of small- to mid-segment pharma/biotech players making significant contributions to drug discovery and development pipelines. Across...

The key focus of this research has been outlined as below: 1. Technology benchmarking and roadmap, market trends, capabilities, and applications targeted: Build a robust strategy by defining the universe of preclinical disease models opportunities and setting key priorities 2. Stakeholder activities, influence, industry initiatives: Evaluate opport...

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) delivers provides strategic insights into breakthrough innovations shaping the future of healthcare, life sciences, and precision therapeutics. It highlights advances in AI-enabled diagnostics, metabolic reprogramming, small molecules, deep proteomics, RNA disco...